Literature DB >> 29498533

Galectin-3 in the pathogenesis of heart failure: a causative mediator or simply a biomarker?

Jonathan A Kirk1, Nikolaos G Frangogiannis2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29498533      PMCID： PMC6032078          DOI： 10.1152/ajpheart.00150.2018

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN： 0363-6135            Impact factor:   4.733


× No keyword cloud information.
  10 in total

Review 1.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  Circulation       Date:  2017-04-28       Impact factor: 29.690

2.  Upregulated galectin-3 is not a critical disease mediator of cardiomyopathy induced by β2-adrenoceptor overexpression.

Authors:  My-Nhan Nguyen; Yidan Su; Helen Kiriazis; Yan Yang; Xiao-Ming Gao; Julie R McMullen; Anthony M Dart; Xiao-Jun Du
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-02-09       Impact factor: 4.733

3.  A role for galectin-3 in the development of early molecular alterations in short-term aortic stenosis.

Authors:  Vanessa Arrieta; Ernesto Martinez-Martinez; Jaime Ibarrola; Virginia Alvarez; Rafael Sádaba; Amaia Garcia-Peña; Amaya Fernández-Celis; Victoria Cachofeiro; Patrick Rossignol; Natalia López-Andrés
Journal:  Clin Sci (Lond)       Date:  2017-03-30       Impact factor: 6.124

4.  Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis.

Authors:  Lili Yu; Willem P T Ruifrok; Maxi Meissner; Eelke M Bos; Harry van Goor; Bahram Sanjabi; Pim van der Harst; Bertram Pitt; Irwin J Goldstein; Jasper A Koerts; Dirk J van Veldhuisen; Ruud A Bank; Wiek H van Gilst; Herman H W Silljé; Rudolf A de Boer
Journal:  Circ Heart Fail       Date:  2012-12-10       Impact factor: 8.790

5.  Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice.

Authors:  Giuseppe Vergaro; Mathilde Prud'homme; Loubina Fazal; Regine Merval; Claudio Passino; Michele Emdin; Jane-Lise Samuel; Alain Cohen Solal; Claude Delcayre
Journal:  Hypertension       Date:  2016-01-18       Impact factor: 10.190

6.  Galectin-3 Participates in Cardiovascular Remodeling Associated With Obesity.

Authors:  Ernesto Martínez-Martínez; Natalia López-Ándres; Raquel Jurado-López; Elodie Rousseau; Mará Visitación Bartolomé; Amaya Fernández-Celis; Patrick Rossignol; Fabian Islas; Alfonso Antequera; Santiago Prieto; María Luaces; Victoria Cachofeiro
Journal:  Hypertension       Date:  2015-09-08       Impact factor: 10.190

7.  The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.

Authors:  Laurent Calvier; Ernesto Martinez-Martinez; Maria Miana; Victoria Cachofeiro; Elodie Rousseau; J Rafael Sádaba; Faiez Zannad; Patrick Rossignol; Natalia López-Andrés
Journal:  JACC Heart Fail       Date:  2014-11-11       Impact factor: 12.035

8.  Myocardial Galectin-3 Expression Is Associated with Remodeling of the Pressure-Overloaded Heart and May Delay the Hypertrophic Response without Affecting Survival, Dysfunction, and Cardiac Fibrosis.

Authors:  Olga Frunza; Ilaria Russo; Amit Saxena; Arti V Shinde; Claudio Humeres; Waqas Hanif; Vikrant Rai; Ya Su; Nikolaos G Frangogiannis
Journal:  Am J Pathol       Date:  2016-03-03       Impact factor: 4.307

9.  Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension.

Authors:  Ernesto Martínez-Martínez; Laurent Calvier; Amaya Fernández-Celis; Elodie Rousseau; Raquel Jurado-López; Luciana V Rossoni; Frederic Jaisser; Faiez Zannad; Patrick Rossignol; Victoria Cachofeiro; Natalia López-Andrés
Journal:  Hypertension       Date:  2015-08-03       Impact factor: 10.190

Review 10.  Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z.

Authors:  Salvatore Sciacchitano; Luca Lavra; Alessandra Morgante; Alessandra Ulivieri; Fiorenza Magi; Gian Paolo De Francesco; Carlo Bellotti; Leila B Salehi; Alberto Ricci
Journal:  Int J Mol Sci       Date:  2018-01-26       Impact factor: 5.923
  10 in total
  2 in total

1.  Moving galectin-3 closer to the goal line.

Authors:  Jonathan A Kirk; Rudolf A de Boer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-12-21       Impact factor: 4.733

Review 2.  β-Adrenoceptor activation affects galectin-3 as a biomarker and therapeutic target in heart disease.

Authors:  Xiao-Jun Du; Wei-Bo Zhao; My-Nhan Nguyen; Qun Lu; Helen Kiriazis
Journal:  Br J Pharmacol       Date:  2019-04-07       Impact factor: 8.739
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.